Prognostic models for predicting relapse or recurrence of major depressive disorder in adults.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
06 05 2021
Historique:
entrez: 6 5 2021
pubmed: 7 5 2021
medline: 22 6 2021
Statut: epublish

Résumé

Relapse (the re-emergence of depressive symptoms after some level of improvement but preceding recovery) and recurrence (onset of a new depressive episode after recovery) are common in depression, lead to worse outcomes and quality of life for patients and exert a high economic cost on society. Outcomes can be predicted by using multivariable prognostic models, which use information about several predictors to produce an individualised risk estimate. The ability to accurately predict relapse or recurrence while patients are well (in remission) would allow the identification of high-risk individuals and may improve overall treatment outcomes for patients by enabling more efficient allocation of interventions to prevent relapse and recurrence. To summarise the predictive performance of prognostic models developed to predict the risk of relapse, recurrence, sustained remission or recovery in adults with major depressive disorder who meet criteria for remission or recovery. We searched the Cochrane Library (current issue); Ovid MEDLINE (1946 onwards); Ovid Embase (1980 onwards); Ovid PsycINFO (1806 onwards); and Web of Science (1900 onwards) up to May 2020. We also searched sources of grey literature, screened the reference lists of included studies and performed a forward citation search. There were no restrictions applied to the searches by date, language or publication status . We included development and external validation (testing model performance in data separate from the development data) studies of any multivariable prognostic models (including two or more predictors) to predict relapse, recurrence, sustained remission, or recovery in adults (aged 18 years and over) with remitted depression, in any clinical setting. We included all study designs and accepted all definitions of relapse, recurrence and other related outcomes. We did not specify a comparator prognostic model. Two review authors independently screened references; extracted data (using a template based on the CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS)); and assessed risks of bias of included studies (using the Prediction model Risk Of Bias ASsessment Tool (PROBAST)). We referred any disagreements to a third independent review author. Where we found sufficient (10 or more) external validation studies of an individual model, we planned to perform a meta-analysis of its predictive performance, specifically with respect to its calibration (how well the predicted probabilities match the observed proportions of individuals that experience the outcome) and discrimination (the ability of the model to differentiate between those with and without the outcome). Recommendations could not be qualified using the GRADE system, as guidance is not yet available for prognostic model reviews. We identified 11 eligible prognostic model studies (10 unique prognostic models). Seven were model development studies; three were model development and external validation studies; and one was an external validation-only study. Multiple estimates of performance measures were not available for any of the models and, meta-analysis was therefore not possible. Ten out of the 11 included studies were assessed as being at high overall risk of bias. Common weaknesses included insufficient sample size, inappropriate handling of missing data and lack of information about discrimination and calibration. One paper (Klein 2018) was at low overall risk of bias and presented a prognostic model including the following predictors: number of previous depressive episodes, residual depressive symptoms and severity of the last depressive episode. The external predictive performance of this model was poor (C-statistic 0.59; calibration slope 0.56; confidence intervals not reported). None of the identified studies examined the clinical utility (net benefit) of the developed model. Of the 10 prognostic models identified (across 11 studies), only four underwent external validation. Most of the studies (n = 10) were assessed as being at high overall risk of bias, and the one study that was at low risk of bias presented a model with poor predictive performance. There is a need for improved prognostic research in this clinical area, with future studies conforming to current best practice recommendations for prognostic model development/validation and reporting findings in line with the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement.

Sections du résumé

BACKGROUND
Relapse (the re-emergence of depressive symptoms after some level of improvement but preceding recovery) and recurrence (onset of a new depressive episode after recovery) are common in depression, lead to worse outcomes and quality of life for patients and exert a high economic cost on society. Outcomes can be predicted by using multivariable prognostic models, which use information about several predictors to produce an individualised risk estimate. The ability to accurately predict relapse or recurrence while patients are well (in remission) would allow the identification of high-risk individuals and may improve overall treatment outcomes for patients by enabling more efficient allocation of interventions to prevent relapse and recurrence.
OBJECTIVES
To summarise the predictive performance of prognostic models developed to predict the risk of relapse, recurrence, sustained remission or recovery in adults with major depressive disorder who meet criteria for remission or recovery.
SEARCH METHODS
We searched the Cochrane Library (current issue); Ovid MEDLINE (1946 onwards); Ovid Embase (1980 onwards); Ovid PsycINFO (1806 onwards); and Web of Science (1900 onwards) up to May 2020. We also searched sources of grey literature, screened the reference lists of included studies and performed a forward citation search. There were no restrictions applied to the searches by date, language or publication status .
SELECTION CRITERIA
We included development and external validation (testing model performance in data separate from the development data) studies of any multivariable prognostic models (including two or more predictors) to predict relapse, recurrence, sustained remission, or recovery in adults (aged 18 years and over) with remitted depression, in any clinical setting. We included all study designs and accepted all definitions of relapse, recurrence and other related outcomes. We did not specify a comparator prognostic model.
DATA COLLECTION AND ANALYSIS
Two review authors independently screened references; extracted data (using a template based on the CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS)); and assessed risks of bias of included studies (using the Prediction model Risk Of Bias ASsessment Tool (PROBAST)). We referred any disagreements to a third independent review author. Where we found sufficient (10 or more) external validation studies of an individual model, we planned to perform a meta-analysis of its predictive performance, specifically with respect to its calibration (how well the predicted probabilities match the observed proportions of individuals that experience the outcome) and discrimination (the ability of the model to differentiate between those with and without the outcome). Recommendations could not be qualified using the GRADE system, as guidance is not yet available for prognostic model reviews.
MAIN RESULTS
We identified 11 eligible prognostic model studies (10 unique prognostic models). Seven were model development studies; three were model development and external validation studies; and one was an external validation-only study. Multiple estimates of performance measures were not available for any of the models and, meta-analysis was therefore not possible. Ten out of the 11 included studies were assessed as being at high overall risk of bias. Common weaknesses included insufficient sample size, inappropriate handling of missing data and lack of information about discrimination and calibration. One paper (Klein 2018) was at low overall risk of bias and presented a prognostic model including the following predictors: number of previous depressive episodes, residual depressive symptoms and severity of the last depressive episode. The external predictive performance of this model was poor (C-statistic 0.59; calibration slope 0.56; confidence intervals not reported). None of the identified studies examined the clinical utility (net benefit) of the developed model.
AUTHORS' CONCLUSIONS
Of the 10 prognostic models identified (across 11 studies), only four underwent external validation. Most of the studies (n = 10) were assessed as being at high overall risk of bias, and the one study that was at low risk of bias presented a model with poor predictive performance. There is a need for improved prognostic research in this clinical area, with future studies conforming to current best practice recommendations for prognostic model development/validation and reporting findings in line with the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement.

Identifiants

pubmed: 33956992
doi: 10.1002/14651858.CD013491.pub2
pmc: PMC8102018
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD013491

Subventions

Organisme : Medical Research Council
ID : G0800472
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Références

J Clin Psychiatry. 2010 Aug;71(8):984-91
pubmed: 20797379
Lancet. 2019 Apr 20;393(10181):1577-1579
pubmed: 31007185
J Psychiatr Res. 2018 Sep;104:1-7
pubmed: 29908389
Res Synth Methods. 2019 Mar;10(1):83-98
pubmed: 30067315
Behav Res Ther. 2017 Jul;94:1-8
pubmed: 28437680
Psychoneuroendocrinology. 2012 Jul;37(7):892-902
pubmed: 22094110
Acta Psychiatr Scand. 2010 Sep;122(3):184-91
pubmed: 20003092
J Affect Disord. 2000 Jan-Mar;57(1-3):159-71
pubmed: 10708827
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):463-9
pubmed: 19302831
Am J Psychiatry. 2008 Jul;165(7):855-62
pubmed: 18450930
Psychol Med. 2018 Jul;48(10):1685-1693
pubmed: 29173194
Depress Anxiety. 2019 Mar;36(3):252-261
pubmed: 30516871
Cochrane Database Syst Rev. 2021 May 6;5:CD013491
pubmed: 33956992
Arch Gen Psychiatry. 2008 Dec;65(12):1368-76
pubmed: 19047523
Ann Intern Med. 2019 Jan 1;170(1):51-58
pubmed: 30596875
J Affect Disord. 2009 Apr;114(1-3):263-70
pubmed: 18805590
Arch Gen Psychiatry. 1992 Oct;49(10):802-8
pubmed: 1417433
Clin Psychol Rev. 2011 Dec;31(8):1349-60
pubmed: 22020371
Stat Methods Med Res. 2019 Sep;28(9):2768-2786
pubmed: 30032705
Stat Methods Med Res. 2018 Nov;27(11):3505-3522
pubmed: 28480827
Lancet. 2003 Feb 22;361(9358):653-61
pubmed: 12606176
Behav Cogn Psychother. 2019 Sep;47(5):514-529
pubmed: 30894231
J Am Acad Child Adolesc Psychiatry. 1994 Jul-Aug;33(6):809-18
pubmed: 7598758
Am J Psychiatry. 1999 Jul;156(7):1000-6
pubmed: 10401442
J Clin Psychiatry. 1997 Jul;58(7):298-306
pubmed: 9269250
Depress Anxiety. 2018 Jul;35(7):658-667
pubmed: 29749006
Lancet Psychiatry. 2016 Mar;3(3):243-50
pubmed: 26803397
Int J Geriatr Psychiatry. 2000 Feb;15(2):112-9
pubmed: 10679842
J Affect Disord. 2000 Jan-Mar;57(1-3):139-45
pubmed: 10708825
BMJ. 2019 May 29;365:l2154
pubmed: 31142454
Arch Gen Psychiatry. 1991 Sep;48(9):851-5
pubmed: 1929776
J Affect Disord. 2020 Nov 1;276:945-953
pubmed: 32745831
Ann Intern Med. 2019 Jan 1;170(1):W1-W33
pubmed: 30596876
BMC Med Res Methodol. 2016 Nov 24;16(1):163
pubmed: 27881078
Br J Psychiatry. 2018 Sep;213(3):509-510
pubmed: 30113285
PLoS Med. 2013;10(2):e1001381
pubmed: 23393430
J Affect Disord. 2013 May;147(1-3):225-31
pubmed: 23218899
Depress Anxiety. 2011 Nov;28(11):955-62
pubmed: 21898715
Br J Psychiatry. 2004 Feb;184:153-6
pubmed: 14754828
Am J Psychiatry. 1998 Oct;155(10):1443-5
pubmed: 9766780
J Affect Disord. 2010 Jul;124(1-2):60-7
pubmed: 20004476
J Am Board Fam Med. 2017 May-Jun;30(3):281-287
pubmed: 28484060
J Affect Disord. 2008 Jan;105(1-3):267-71
pubmed: 17574685
Clin Psychol Rev. 2015 Nov;41:16-26
pubmed: 25754289
Heart. 2012 May;98(9):691-8
pubmed: 22397946
Depress Anxiety. 2009;26(7):682-8
pubmed: 19170101
J Affect Disord. 1998 Sep;50(2-3):97-108
pubmed: 9858069
Psychopharmacol Bull. 2009;42(1):94-107
pubmed: 19204654
Am J Psychiatry. 1992 Aug;149(8):1046-52
pubmed: 1636804
Stat Med. 2019 Mar 30;38(7):1276-1296
pubmed: 30357870
Transl Psychiatry. 2017 Dec 8;7(12):1270
pubmed: 29217832
BMC Med Res Methodol. 2014 Mar 19;14:40
pubmed: 24645774
Psychiatr Serv. 1999 Mar;50(3):376-80
pubmed: 10096642
CMAJ. 2011 Nov 22;183(17):1969-76
pubmed: 22025655
Clin Psychol Rev. 2007 Dec;27(8):959-85
pubmed: 17448579
Psychol Med. 2013 Jan;43(1):39-48
pubmed: 23111147
Ann Intern Med. 2015 Jan 6;162(1):W1-73
pubmed: 25560730
Cochrane Database Syst Rev. 2019 Dec 23;12:CD013299
pubmed: 31868236
Psychopharmacol Bull. 1973 Jan;9(1):13-28
pubmed: 4682398
J Clin Psychiatry. 2006 May;67(5):747-55
pubmed: 16841624
BMJ. 2015 Mar 16;350:h870
pubmed: 25775931
J Affect Disord. 2013 Oct;151(1):59-65
pubmed: 23790554
Psychiatr Q. 2015 Sep;86(3):407-17
pubmed: 25597030
Clin Psychol Rev. 2015 Jul;39:58-70
pubmed: 25939032
BMJ. 2013 Feb 05;346:e5595
pubmed: 23386360
Diagn Progn Res. 2020 Jun 4;4:6
pubmed: 32607451
BMJ. 2020 Mar 18;368:m441
pubmed: 32188600
BMC Psychiatry. 2019 Dec 11;19(1):391
pubmed: 31829206
Am J Psychiatry. 2016 Nov 1;173(11):1140-1146
pubmed: 27418380
Psychiatr Serv. 2007 Aug;58(8):1049-56
pubmed: 17664515
JAMA. 1983 Dec 23-30;250(24):3299-304
pubmed: 6645026
Eur Arch Psychiatry Clin Neurosci. 2013 Aug;263(5):413-23
pubmed: 23108435
JAMA Psychiatry. 2020 May 1;77(5):513-522
pubmed: 32074255
Arch Fam Med. 1998 Sep-Oct;7(5):443-9
pubmed: 9755737
Psychol Med. 2011 Jan;41(1):141-50
pubmed: 20346195
Psychol Med. 2003 Jul;33(5):839-45
pubmed: 12877398
Clin Psychol Rev. 2018 Aug;64:13-38
pubmed: 30075313
J Clin Epidemiol. 2020 May;121:62-70
pubmed: 31982539
Front Psychiatry. 2019 Mar 28;10:145
pubmed: 30984039
Am J Psychiatry. 1989 Jun;146(6):764-7
pubmed: 2729427
J Affect Disord. 2009 Mar;113(3):263-71
pubmed: 18625521
J Affect Disord. 2019 Jan 15;243:48-54
pubmed: 30223139
Neuropsychopharmacology. 2006 Sep;31(9):1841-53
pubmed: 16794566
BMC Med Res Methodol. 2014 Dec 22;14:137
pubmed: 25532820
Depress Anxiety. 2014 May;31(5):451-7
pubmed: 24877248
J Affect Disord. 2015 Jul 15;180:52-61
pubmed: 25881281
Am J Psychiatry. 1992 Aug;149(8):999-1010
pubmed: 1353322
BMJ. 2017 Jan 5;356:i6460
pubmed: 28057641
J Affect Disord. 2010 Sep;125(1-3):221-6
pubmed: 20303600
Syst Rev. 2013 Sep 05;2:71
pubmed: 24007720
Biol Psychiatry. 2006 Apr 15;59(8):696-701
pubmed: 16368077
BMJ. 2016 Jan 25;352:i6
pubmed: 26810254
Psychother Res. 2021 Jan;31(1):19-32
pubmed: 32114926

Auteurs

Andrew S Moriarty (AS)

Mental Health and Addiction Research Group, Department of Health Sciences, University of York, York, UK.
Hull York Medical School, University of York, York, UK.

Nicholas Meader (N)

Centre for Reviews and Dissemination, University of York, York, UK.
Cochrane Common Mental Disorders, University of York, York, UK.

Kym Ie Snell (KI)

Centre for Prognosis Research, School of Medicine, Keele University, Keele, UK.

Richard D Riley (RD)

Centre for Prognosis Research, School of Medicine, Keele University, Keele, UK.

Lewis W Paton (LW)

Mental Health and Addiction Research Group, Department of Health Sciences, University of York, York, UK.

Carolyn A Chew-Graham (CA)

School of Medicine, Keele University, Keele, UK.

Simon Gilbody (S)

Mental Health and Addiction Research Group, Department of Health Sciences, University of York, York, UK.
Hull York Medical School, University of York, York, UK.

Rachel Churchill (R)

Centre for Reviews and Dissemination, University of York, York, UK.
Cochrane Common Mental Disorders, University of York, York, UK.

Robert S Phillips (RS)

Centre for Reviews and Dissemination, University of York, York, UK.

Shehzad Ali (S)

Mental Health and Addiction Research Group, Department of Health Sciences, University of York, York, UK.
Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, Canada.

Dean McMillan (D)

Mental Health and Addiction Research Group, Department of Health Sciences, University of York, York, UK.
Hull York Medical School, University of York, York, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH